Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Aromasin (exemestane) [legacy through FY25] by Year
Aromasin (exemestane) [legacy through FY25] ($M) ($M)
Pfizer Aromasin (exemestane) [legacy through FY25]: $450M in FY2025, up 29.7% from a year earlier.
Latest, FY2025
450
Period ended Dec 31, 2025
Change on a year earlier
+29.7%
347 in FY2024
History
7 years
Since FY2019
Sources
4
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-K Segment Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Aromasin (exemestane) [legacy through FY25] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 450 | +29.7% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 347 | +15.3% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 301 | +21.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 248 | +17.5% | Form 10-K (filed 2024-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 211 | +42.6% | Form 10-K (filed 2024-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 148 | +8.8% | Form 10-K (filed 2023-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 136 | – | Form 10-K (filed 2022-02-24) ↗ |
Cite this data
StockData. (2026). Pfizer Aromasin (exemestane) [legacy through FY25] ($M), annual FY2019–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/aromasin-leg
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.